Natera Inc.
Natera Announces Strong Preliminary Q4 and Full-Year 2024 Financial Results
Summary
Natera, Inc. announced preliminary unaudited results for the fourth quarter and full year of 2024, showing significant revenue growth and test processing increases. The company reported an approximate 52% increase in Q4 revenues to $472 million and a 56% increase in full-year revenues to $1.7 billion. Test processing also saw notable growth, with oncology tests processing increasing by 54.7% in Q4 and 54.9% for the full year. Non-GAAP cash inflows were positive for both Q4 and the full year, indicating improved operational cash generating capabilities.
Profitelligence Alerts
Get alerts for NTRA
Be first to know when Natera Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Official SEC Documents
Advertisement